Concert Pharmaceuticals, Inc. (CNCE)

NASDAQ: CNCE · IEX Real-Time Price · USD
3.01 -0.14 (-4.44%)
Jan 18, 2022 3:00 PM EST - Market open
Market Cap104.33M
Revenue (ttm)32.57M
Net Income (ttm)-66.31M
Shares Out34.66M
EPS (ttm)-1.97
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume46,716
Open3.10
Previous Close3.15
Day's Range3.00 - 3.15
52-Week Range2.64 - 12.18
Beta0.27
AnalystsStrong Buy
Price Target13.00 (+331.9%)
Earnings DateNov 9, 2021

About CNCE

Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that develops novel small molecule drugs for the treatment of autoimmune diseases. Its lead product candidate is CTP-543, which is in Phase III clinical trial for the treatment of alopecia areata, a serious autoimmune dermatological condition. Concert Pharmaceuticals has strategic collaborations with Avanir Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Cipla Technologies; and Processa Pharmaceuticals. The company was incorporated in 2006 and is headquarter...

IndustryBiotechnology
IPO DateFeb 13, 2014
CEORoger Tung
Employees71
Stock ExchangeNASDAQ
Ticker SymbolCNCE
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 6 analysts, the average rating for CNCE stock is "Strong Buy." The 12-month stock price forecast is 13.00, which is an increase of 331.89% from the latest price.

Price Target
$13.00
(331.89% upside)
Analyst Consensus: Strong Buy

News

Concert Pharmaceuticals Completes Enrollment in THRIVE-AA2 Phase 3 Clinical Trial Evaluating CTP-543 for Alopecia Areata

LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #AlopeciaAreata--Concert completed patient enrollment in the CTP-543 THRIVE-AA2 Phase 3 trial for alopecia areata.

2 weeks ago - Business Wire

Concert Pharmaceuticals to Present at H.C. Wainwright BIOCONNECT Virtual Conference

LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #AlopeciaAreata--Concert to Participate in the H.C. Wainwright BIOCONNECT Conference.

2 weeks ago - Business Wire

Concert Pharmaceuticals to Participate in Fireside Chat at Jefferies London Healthcare Conferences

LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #AlopeciaAreata--Concert's on-demand fireside chat at the Jefferies London conference will be available beginning at 8:00 a.m. GMT on November 18, 2021.

2 months ago - Business Wire

Are These Penny Stocks Worth Being Bullish On? 3 to Watch

Check these penny stocks out for your watchlist in November The post Are These Penny Stocks Worth Being Bullish On? 3 to Watch appeared first on Penny Stocks to Buy, Picks, News and Information | PennyS...

Other symbols:CCORETO
2 months ago - PennyStocks

Concert Pharmaceuticals (CNCE) Reports Q3 Loss, Tops Revenue Estimates

Concert (CNCE) delivered earnings and revenue surprises of -2.63% and 117.20%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Concert Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Company Update

LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #AlopeciaAreata--Concert reports financial results for the third quarter of 2021.

2 months ago - Business Wire

Are These Trending Penny Stocks Worth Buying at Current Levels?

Check these trending penny stocks out for your watchlist The post Are These Trending Penny Stocks Worth Buying at Current Levels? appeared first on Penny Stocks to Buy, Picks, News and Information | Pen...

Other symbols:ARTLPETZ
2 months ago - PennyStocks

Why These Penny Stocks Popped Today, 3 to Watch

Are these penny stocks on your November watchlist? The post Why These Penny Stocks Popped Today, 3 to Watch appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Other symbols:ITPPETZ
2 months ago - PennyStocks

Concert Pharmaceuticals Announces $65 Million Financing

LEXINGTON, Mass.--(BUSINESS WIRE)--Concert Pharmaceuticals entered into an agreement with BVF Partners and RA Capital to raise gross proceeds of $65 million.

2 months ago - Business Wire

Concert Pharmaceuticals to Report Third Quarter 2021 Results on November 9, 2021

LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #AlopeciaAreata--Concert to report third quarter 2021 financial results before the market open on November 9, 2021.

2 months ago - Business Wire

Earnings Preview: Concert Pharmaceuticals (CNCE) Q3 Earnings Expected to Decline

Concert (CNCE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

Concert Pharmaceuticals Completes Enrollment in THRIVE-AA1 Phase 3 Clinical Trial Evaluating CTP-543 for Alopecia Areata

LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #AlopeciaAreata--Concert completed patient enrollment in the CTP-543 THRIVE-AA1 Phase 3 trial.

2 months ago - Business Wire

Concert Pharmaceuticals to Present at Upcoming Investor Conferences

LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #AlopeciaAreata--In September, Concert will present virtually at the HC Wainwright and Cantor healthcare conferences.

4 months ago - Business Wire

Concert Pharmaceuticals Reports Second Quarter 2021 Financial Results

LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #AlopeciaAreata--Concert reports financial results for the second quarter of 2021.

5 months ago - Business Wire

Analysts Estimate Concert Pharmaceuticals (CNCE) to Report a Decline in Earnings: What to Look Out for

Concert (CNCE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

5 months ago - Zacks Investment Research

Concert Pharmaceuticals to Report Second Quarter 2021 Results on August 5, 2021

LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #AlopeciaAreata--The Company will host a conference call and webcast on August 5, 2021 to discuss its second quarter financial results and provide a business ...

5 months ago - Business Wire

Concert Pharma Sees US Application Submission For Patchy Hair Loss Candidate In 2023

Concert Pharmaceuticals Inc (NASDAQ: CNCE) has announced updated data from its ongoing open-label, long-term extension study of CTP-543 in patients with moderate to severe alopecia areata. Alopecia area...

6 months ago - Benzinga

Concert Pharmaceuticals Presents Update on CTP-543 Long-Term Extension Study in Alopecia Areata During 2nd JAK Inhibi...

LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #AlopeciaAreata--Concert will provide an update on the CTP-543 open label, long-term extension study at the 2nd JAK Inhibitors Drug Development Summit.

6 months ago - Business Wire

Concert (CNCE) Initiates Second Phase III Hair Loss Study

Concert Pharmaceuticals (CNCE) is developing its lead pipeline candidate, CTP-543, for treating alopecia areata. Two late-stage studies are evaluating the candidate in AA patients to support a potential...

7 months ago - Zacks Investment Research

Concert Pharmaceuticals Initiates THRIVE-AA2 Phase 3 Clinical Trial Evaluating CTP-543 for Alopecia Areata

LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #AlopeciaAreata--Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced it has initiated THRIVE-AA2, the second planned Phase 3 clinical trial to evalua...

7 months ago - Business Wire

Concert Pharmaceuticals Announces Sale of VX-561 Milestones to Vertex for $32 Million

LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #Concert--Concert announced that Vertex purchased the potential future milestones under their 2017 asset purchase agreement relating to VX-561 for $32 million.

8 months ago - Business Wire

Concert Pharmaceuticals (CNCE) Reports Q1 Loss, Lags Revenue Estimates

Concert (CNCE) delivered earnings and revenue surprises of -1.52% and -99.67%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

8 months ago - Zacks Investment Research

Concert Pharmaceuticals Reports First Quarter 2021 Financial Results

LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #CNCE--Concert reports financial results for the first quarter of 2021.

8 months ago - Business Wire

Concert Pharmaceuticals to Report First Quarter 2021 Results on May 4, 2021

LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #AlopeciaAreata--The Company will host a conference call and webcast on May 4, 2021, to discuss its first quarter 2021 financial results and provide a busines...

8 months ago - Business Wire

Will Concert Pharmaceuticals (CNCE) Report Negative Q1 Earnings? What You Should Know

Concert (CNCE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

8 months ago - Zacks Investment Research